Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18016530 | 0.82 | — | — | |
| SCHEMBL16629720 | 0.77 | — | — | |
| SCHEMBL16629519 | 0.69 | — | — | |
| SCHEMBL18016518 | 0.67 | TSHR (0.35) | TP53 | |
| SCHEMBL270129 | 0.63 | — | — | |
| SCHEMBL4078147 | 0.63 | — | — | |
| SCHEMBL11681921 | 0.63 | TP53 (0.35) | TP53 | |
| SCHEMBL16146089 | 0.61 | TP53 (0.38) | TP53 | |
| Lithium SCHEMBL29750311 | 0.61 | TP53 (0.38) | TP53 | |
| SCHEMBL16146263 | 0.61 | TP53 (0.38) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2016-08-18 | — | — | US | disclosed |
| WO-2015051169-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237108-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | NSUN3, POLRMT, TRDMT1 | TP53 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.